Suscribirse

Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome - 19/06/13

Doi : 10.1016/j.amjmed.2012.12.015 
Wai Ping A. Chan, MBBS, PhD, Doan T. Ngo, PhD, Aaron L. Sverdlov, MBBS, PhD, Sharmalar Rajendran, MBBS, PhD, Irene Stafford, BSc, Tamila Heresztyn, BSc, Yuliy Y. Chirkov, PhD, John D. Horowitz, MBBS, PhD
Cardiology Unit, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Department of Medicine, University of Adelaide, South Australia, Australia 

Requests for reprints should be addressed to John D. Horowitz, MBBS, PhD, Cardiology Unit, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, South Australia 5011, Australia.

Abstract

Objective

The objective of this study was to compare the impact of aging on nitric oxide (NO) modulation of platelet and vascular function in healthy women and women with polycystic ovary syndrome.

Methods and Results

A case-control study of women ages 18 to 60 years, comparing women with polycystic ovarian syndrome against age-matched healthy controls, was performed. A total of 242 women, of whom 109 had polycystic ovarian syndrome (based on Rotterdam criteria), participated in the study. Women who were pregnant or on clopidogrel were excluded from the study. Inhibition of platelet aggregation by nitric oxide (primary outcome measure), vascular endothelial function, plasma concentrations of NG, NG-dimethyl-L-arginine (ADMA), endothelial progenitor cell count, and high-sensitivity C-reactive protein (markers of endothelial dysfunction and inflammation) were assessed. With increasing age in control women, there was progressive attenuation of platelet responses to NO, impairment of endothelial function, and elevation of ADMA levels (P ≤.001). Irrespective of age, women with polycystic ovarian syndrome exhibited greater impairment of all these parameters (all P <.05, 2-way analysis of variance) and demonstrated these anomalies earlier in life.

Conclusions

Normal aging in women is associated with attenuation of NO-based signaling in platelets and blood vessels. In women with polycystic ovarian syndrome, these changes are present from early adult life and may contribute to premature atherogenesis.

El texto completo de este artículo está disponible en PDF.

Keywords : Aging, Nitric oxide, Polycystic ovary syndrome, Women


Esquema


 Funding: This study was funded in part by the Cardiovascular Lipid Disorders research grant (Pfizer, Australia), and departmental funding. WC and AS were recipients of postgraduate research scholarships from the University of Adelaide and Cardiovascular Lipid Disorders research grants (Pfizer, West Ryde, NSW, Australia).
 Conflict of Interest: None.
 Authorship: All authors had access to the data and a role in preparation of the manuscript.


© 2013  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 126 - N° 7

P. 640.e1-640.e7 - juillet 2013 Regresar al número
Artículo precedente Artículo precedente
  • Prevalence of Covert Duplicate Publications in Budd-Chiari Syndrome Articles in China: A Systematic Analysis
  • Xingshun Qi, Weirong Ren, Lei Liu, Zhiping Yang, Man Yang, Daiming Fan, Guohong Han
| Artículo siguiente Artículo siguiente
  • Body Mass Index and Adverse Events in Patients with Incident Atrial Fibrillation
  • Thure Filskov Overvad, Lars Hvilsted Rasmussen, Flemming Skjøth, Kim Overvad, Gregory Y.H. Lip, Torben Bjerregaard Larsen

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.